IAM
TGTX icon

Innovis Asset Management’s TG Therapeutics TGTX Stock Holding History

Innovis Asset Management’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		$310K Buy
37,049
+16,607
+81% +$232K 0.12% 103
2023
Q2 		$508K Buy
+20,442
New +$528K 0.19% 71

Other funds holding TGTX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

Innovis Asset Management's TGTX Position: Q3 2023 in Review

Innovis Asset Management increased its TG Therapeutics (TGTX) stake by 81% in Q3 2023, buying an estimated $232K and bringing the position to 37,049 shares worth $310K. The position accounts for 0.12% of the portfolio, ranked #103.

Innovis Asset Management first reported a position in TGTX in Q2 2023 and has held it in 2 quarters since. The position peaked at $508K in Q2 2023. 235 funds tracked by Wall St. Rank hold TGTX as of Q3 2023.

  • Innovis Asset Management held 37,049 shares of TG Therapeutics worth $310K as of Q3 2023.
  • Innovis Asset Management bought 16,607 TG Therapeutics shares in Q3 2023, an estimated $232K.
  • TG Therapeutics made up 0.12% of Innovis Asset Management's portfolio in Q3 2023, its #103 holding.
  • Innovis Asset Management first reported a position in TG Therapeutics in Q2 2023 and has held it in 2 quarters since.
  • Innovis Asset Management's TG Therapeutics position peaked at $508K in Q2 2023.
  • 235 funds tracked by Wall St. Rank held TG Therapeutics as of Q3 2023.

Based on Innovis Asset Management's 13F filing for Q3 2023, filed 9 Nov 2023.